JP7618581B2 - 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 - Google Patents
9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 Download PDFInfo
- Publication number
- JP7618581B2 JP7618581B2 JP2021562980A JP2021562980A JP7618581B2 JP 7618581 B2 JP7618581 B2 JP 7618581B2 JP 2021562980 A JP2021562980 A JP 2021562980A JP 2021562980 A JP2021562980 A JP 2021562980A JP 7618581 B2 JP7618581 B2 JP 7618581B2
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- zfp
- seq
- c9orf72
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025002919A JP7888768B2 (ja) | 2019-04-23 | 2025-01-08 | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837523P | 2019-04-23 | 2019-04-23 | |
| US62/837,523 | 2019-04-23 | ||
| US202062964844P | 2020-01-23 | 2020-01-23 | |
| US62/964,844 | 2020-01-23 | ||
| PCT/US2020/029590 WO2020219726A1 (en) | 2019-04-23 | 2020-04-23 | Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002919A Division JP7888768B2 (ja) | 2019-04-23 | 2025-01-08 | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529500A JP2022529500A (ja) | 2022-06-22 |
| JP2022529500A5 JP2022529500A5 (cg-RX-API-DMAC7.html) | 2023-04-28 |
| JP7618581B2 true JP7618581B2 (ja) | 2025-01-21 |
Family
ID=70680681
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562980A Active JP7618581B2 (ja) | 2019-04-23 | 2020-04-23 | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
| JP2025002919A Active JP7888768B2 (ja) | 2019-04-23 | 2025-01-08 | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002919A Active JP7888768B2 (ja) | 2019-04-23 | 2025-01-08 | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
Country Status (16)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025069161A (ja) * | 2019-04-23 | 2025-04-30 | サンガモ セラピューティクス, インコーポレイテッド | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020131632A1 (en) | 2018-12-20 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated repeat expansion |
| GB202010075D0 (en) * | 2020-07-01 | 2020-08-12 | Imp College Innovations Ltd | Therapeutic nucleic acids, peptides and uses |
| IL311610A (en) | 2021-09-21 | 2024-05-01 | Scribe Therapeutics Inc | Engineered CASX suppressor systems |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015509958A (ja) | 2012-02-29 | 2015-04-02 | サンガモ バイオサイエンシーズ, インコーポレイテッド | ハンチントン病を治療するための方法および組成物 |
| WO2018208972A1 (en) | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| JP4012243B2 (ja) | 1994-01-18 | 2007-11-21 | ザ スクリップス リサーチ インスティチュート | 亜鉛フィンガータンパク質誘導体およびそのための方法 |
| CA2186118C (en) | 1994-03-23 | 2010-10-19 | Richard W. Hanson | Compacted nucleic acids and their delivery to cells |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| CA2196419C (en) | 1994-08-20 | 2007-08-21 | Yen Choo | Improvements in or relating to binding proteins for recognition of dna |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| DE69942334D1 (de) | 1998-03-02 | 2010-06-17 | Massachusetts Inst Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
| CA2329259C (en) | 1998-05-27 | 2003-08-05 | Avigen, Inc. | Convection-enhanced delivery of aav vectors |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6503717B2 (en) | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| AU7866400A (en) | 1999-10-07 | 2001-05-10 | Baylor College Of Medicine | Novel zinc finger protein |
| AU2001250774B2 (en) | 2000-02-08 | 2005-01-27 | Sangamo Biosciences, Inc. | Cells expressing zinc finger proteins for drug discovery |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| ATE360361T1 (de) | 2000-09-28 | 2007-05-15 | Sangamo Biosciences Inc | Kernumprogrammierung bei iswi und ähnlichen chromatinremodellierenden atpasen |
| US20050235369A1 (en) * | 2001-03-28 | 2005-10-20 | Yen Choo | Gene regulation II |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| US7182944B2 (en) | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| EP1463805B1 (en) | 2001-12-17 | 2014-10-22 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| CN1897977A (zh) | 2003-10-20 | 2007-01-17 | Ns基因公司 | 帕金森氏病的体内基因治疗 |
| WO2006042090A1 (en) | 2004-10-05 | 2006-04-20 | Avigen, Inc. | Stepped cannula |
| WO2006121866A2 (en) | 2005-05-05 | 2006-11-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
| JP5238503B2 (ja) | 2005-08-23 | 2013-07-17 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 対流増加送達を用いた治療薬の慢性的な送達のための逆流防止カニューレ及びシステム |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| SI2019683T2 (sl) | 2006-04-25 | 2022-10-28 | The Regents Of The University Of California | Dajanje rastnih faktorjev za zdravljenje motenj CŽS |
| EP2027262B1 (en) | 2006-05-25 | 2010-03-31 | Sangamo Biosciences Inc. | Variant foki cleavage half-domains |
| US7837668B2 (en) | 2006-10-10 | 2010-11-23 | Ceregene, Inc. | Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of same |
| US8153773B2 (en) | 2007-06-19 | 2012-04-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
| JP5763341B2 (ja) | 2007-09-27 | 2015-08-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 生物学的活性のあるヌクレアーゼの迅速なインビボ同定法 |
| AU2009212247A1 (en) | 2008-02-08 | 2009-08-13 | Sangamo Therapeutics, Inc. | Treatment of chronic pain with zinc finger proteins |
| JP5763530B2 (ja) | 2008-06-10 | 2015-08-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | Bax−およびBak−欠損細胞株の生成のための方法および組成物 |
| JP5908725B2 (ja) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 標的一本鎖開裂および標的組込みのための方法、並びに組成物 |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| CA2769262C (en) | 2009-07-28 | 2019-04-30 | Sangamo Biosciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
| EA022786B1 (ru) | 2009-07-31 | 2016-03-31 | Этрис Гмбх | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| JP6137596B2 (ja) | 2010-02-08 | 2017-05-31 | サンガモ セラピューティクス, インコーポレイテッド | 遺伝子操作された切断ハーフドメイン |
| EP2566972B1 (en) | 2010-05-03 | 2020-01-15 | Sangamo Therapeutics, Inc. | Compositions for linking zinc finger modules |
| AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
| WO2013074999A1 (en) | 2011-11-16 | 2013-05-23 | Sangamo Biosciences, Inc. | Modified dna-binding proteins and uses thereof |
| WO2014134351A2 (en) | 2013-02-27 | 2014-09-04 | The Broad Institute, Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
| EP2997146A4 (en) | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| MX391904B (es) | 2013-11-11 | 2025-03-12 | Sangamo Biosciences Inc | Un represor genetico para usarse en el tratamiento de la enfermedad de huntington. |
| KR20160097338A (ko) | 2013-12-12 | 2016-08-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 뉴클레오티드 반복 장애에서의 crispr-cas 시스템의 조성물 및 방법 및 용도 |
| EP3929279A1 (en) | 2014-03-18 | 2021-12-29 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of zinc finger protein expression |
| WO2015153760A2 (en) | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a nervous system disorder |
| BR112016025849A2 (pt) | 2014-05-08 | 2017-10-17 | Chdi Foundation Inc | métodos e composições para o tratamento da doença de huntington |
| US9970001B2 (en) * | 2014-06-05 | 2018-05-15 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease design |
| GB201418965D0 (cg-RX-API-DMAC7.html) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| CA3035810A1 (en) | 2015-09-02 | 2017-03-09 | University Of Massachusetts | Detection of gene loci with crispr arrayed repeats and/or polychromatic single guide ribonucleic acids |
| AU2016359629B2 (en) | 2015-11-23 | 2023-03-09 | Ranjan BATRA | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9 |
| CA3009308A1 (en) * | 2015-12-23 | 2017-06-29 | Chad Albert COWAN | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration |
| WO2018002762A1 (en) * | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders |
| MA46018A (fr) | 2016-08-19 | 2019-06-26 | Bluebird Bio Inc | Activateurs d'édition du génome |
| IL264792B2 (en) | 2016-08-24 | 2023-10-01 | Sangamo Therapeutics Inc | Engineered target-specific zinc-finger nucleases |
| WO2018039471A2 (en) | 2016-08-25 | 2018-03-01 | Trustees Of Boston University | Synthetic transcriptional and epigenetic regulators based on engineered, orthogonal zinc finger proteins |
| CN110214184B (zh) | 2016-12-01 | 2024-07-02 | 桑格摩生物治疗股份有限公司 | τ蛋白调节剂以及用于其递送的方法和组合物 |
| EP3716767A4 (en) | 2017-10-24 | 2021-11-24 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF RARE DISEASES |
| JP7618581B2 (ja) * | 2019-04-23 | 2025-01-21 | サンガモ セラピューティクス, インコーポレイテッド | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
-
2020
- 2020-04-23 JP JP2021562980A patent/JP7618581B2/ja active Active
- 2020-04-23 BR BR112021020868A patent/BR112021020868A2/pt unknown
- 2020-04-23 PH PH1/2021/552554A patent/PH12021552554A1/en unknown
- 2020-04-23 AU AU2020262281A patent/AU2020262281B2/en active Active
- 2020-04-23 US US16/856,774 patent/US12139517B2/en active Active
- 2020-04-23 KR KR1020217037624A patent/KR102981881B1/ko active Active
- 2020-04-23 CN CN202511030848.3A patent/CN120960394A/zh active Pending
- 2020-04-23 CN CN202080031118.4A patent/CN113766921B/zh active Active
- 2020-04-23 KR KR1020267019710A patent/KR20260099235A/ko active Pending
- 2020-04-23 MX MX2021012836A patent/MX2021012836A/es unknown
- 2020-04-23 CA CA3137368A patent/CA3137368A1/en active Pending
- 2020-04-23 EP EP20725373.3A patent/EP3958871A1/en active Pending
- 2020-04-23 TW TW109113701A patent/TWI862584B/zh active
- 2020-04-23 PE PE2021001757A patent/PE20212332A1/es unknown
- 2020-04-23 WO PCT/US2020/029590 patent/WO2020219726A1/en not_active Ceased
- 2020-04-23 SG SG11202111443SA patent/SG11202111443SA/en unknown
-
2021
- 2021-10-19 IL IL287384A patent/IL287384A/en unknown
- 2021-11-23 CO CONC2021/0015653A patent/CO2021015653A2/es unknown
-
2024
- 2024-11-09 US US18/942,681 patent/US20250066433A1/en active Pending
- 2024-11-11 US US18/943,130 patent/US20250066434A1/en active Pending
-
2025
- 2025-01-08 JP JP2025002919A patent/JP7888768B2/ja active Active
-
2026
- 2026-06-23 AU AU2026204876A patent/AU2026204876A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015509958A (ja) | 2012-02-29 | 2015-04-02 | サンガモ バイオサイエンシーズ, インコーポレイテッド | ハンチントン病を治療するための方法および組成物 |
| WO2018208972A1 (en) | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
Non-Patent Citations (1)
| Title |
|---|
| Acta Neuropathologica Communications,2016年,Volume 4, Article number: 18 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025069161A (ja) * | 2019-04-23 | 2025-04-30 | サンガモ セラピューティクス, インコーポレイテッド | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
| JP7888768B2 (ja) | 2019-04-23 | 2026-07-13 | サンガモ セラピューティクス, インコーポレイテッド | 9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2026204876A1 (en) | 2026-07-16 |
| CN120960394A (zh) | 2025-11-18 |
| JP7888768B2 (ja) | 2026-07-13 |
| US20250066434A1 (en) | 2025-02-27 |
| CO2021015653A2 (es) | 2022-01-17 |
| BR112021020868A2 (pt) | 2021-12-14 |
| KR102981881B1 (ko) | 2026-06-25 |
| AU2020262281A1 (en) | 2021-11-04 |
| WO2020219726A1 (en) | 2020-10-29 |
| PH12021552554A1 (en) | 2022-07-04 |
| IL287384A (en) | 2021-12-01 |
| SG11202111443SA (en) | 2021-11-29 |
| CN113766921A (zh) | 2021-12-07 |
| CA3137368A1 (en) | 2020-10-29 |
| TW202104249A (zh) | 2021-02-01 |
| CN113766921B (zh) | 2025-08-15 |
| KR20260099235A (ko) | 2026-06-26 |
| AU2020262281B2 (en) | 2026-03-26 |
| US12139517B2 (en) | 2024-11-12 |
| US20250066433A1 (en) | 2025-02-27 |
| JP2025069161A (ja) | 2025-04-30 |
| PE20212332A1 (es) | 2021-12-14 |
| TWI862584B (zh) | 2024-11-21 |
| US20200339638A1 (en) | 2020-10-29 |
| JP2022529500A (ja) | 2022-06-22 |
| KR20220003561A (ko) | 2022-01-10 |
| EP3958871A1 (en) | 2022-03-02 |
| TW202521561A (zh) | 2025-06-01 |
| MX2021012836A (es) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250066433A1 (en) | Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof | |
| JP2021521152A (ja) | 抑制性ニューロンにおける電位開口型ナトリウムチャネルのレスキュー | |
| JP2016517278A (ja) | スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法 | |
| JP7824873B2 (ja) | プリオン病の治療のためのジンクフィンガータンパク質転写因子 | |
| TW202206446A (zh) | 用於治療tdp-43蛋白質病變之組合物及方法 | |
| US20230242602A1 (en) | Zinc finger protein transcription factors for repressing tau expression | |
| KR20210070344A (ko) | 타우 단백질의 조정을 위한 방법 및 조성물 | |
| TWI888417B (zh) | 用於抑制α-突觸核蛋白(SYNUCLEIN)表現之鋅指蛋白轉錄因子 | |
| RU2828216C2 (ru) | Модуляторы экспрессии гена открытой рамки считывания 72 хромосомы 9 и их применения | |
| CA3140507A1 (en) | Insulin gene therapy | |
| KR20250173522A (ko) | Nav1.7 발현 억제를 위한 아연 집게 단백질 전사 인자 | |
| JP2023545972A (ja) | アルファ-シヌクレイン発現を抑制するための新規ジンクフィンガータンパク質転写因子 | |
| KR102640462B1 (ko) | 신경병증성 통증의 치료를 위한 방법 및 조성물 | |
| TW202233655A (zh) | 用於治療阿茲海默症之組合物及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230420 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230420 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240326 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240502 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240625 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241126 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241210 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250108 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7618581 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |